Belle Van Rosmalen
Director, Medical Development Eli Lilly
Belle Van Rosmalen, MD, currently serves as the Director of Medical Development at Eli Lilly and Company, where she leverages her extensive clinical expertise and research background to drive innovative initiatives in Hepatology and Oncology. In her role, Belle oversees the strategic development and execution of clinical programs aimed at advancing therapeutic options for patients with liver diseases and cancers, ensuring alignment with regulatory standards and scientific rigor. Her deep understanding of clinical research methodologies, both qualitative and quantitative, enables her to design and interpret complex studies that inform the development of novel treatments and optimize patient outcomes.
Seminars
Wednesday 15th April 2026
Adopting Innovative Trial design & Endpoints in High-risk MASLD
3:30 pm
- Positive changes in the regulatory landscape of non-invasive tests, pushing the boundaries and reducing the need for invasive liver biopsies.
- The concept of High-risk MASLD
- The innovative phase 3 trial design of Lilly’s SYNERGY-Outcomes trial; mimicking clinical practice, streamline the entire development process and lower the cost of bringing a drug to approval while improving recruitment and retention
